Press Releases

Date Title and Summary View
Toggle Summary Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
  NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced interim 8-week Phase 2a results for its next-generation neuromodulator
View HTML
Toggle Summary Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018
- Reports 2017 Unaudited Year-End Cash and Investments Balance Exceeded $280 million - - Expects to Complete RT002 SAKURA Phase 3 Program and Start RT002 Phase 3 Trial for Cervical Dystonia in 2018 - - Plantar Fasciitis Phase 2a Interim Results by Mid-January - NEWARK, Calif.
View HTML
Toggle Summary Revance Announces Closing of Public Offering of Common Stock
Gross Proceeds of Offering Total $167.1 Million NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the
View HTML
Toggle Summary Revance Announces Pricing of Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public offering of
View HTML
Toggle Summary Revance Announces Proposed Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in which it will
View HTML
Toggle Summary Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
- Highly statistically significant results on primary composite endpoint achieved at Week 4 - - RT002 delivered highly statistically significant reduction in severity of glabellar lines at Week 24 - - If approved, RT002 could represent a new, next-generation, long-acting neuromodulator - - Revance
View HTML
Toggle Summary Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia
- Company completes End-of-Phase 2 Meeting with FDA - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its End-of-Phase 2
View HTML
Toggle Summary Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the
View HTML
Toggle Summary Revance Releases Third Quarter 2017 Results
-SAKURA 1 & 2 Phase 3 pivotal trials on track to report topline results before year-end 2017- -SAKURA 3 open-label safety study for glabellar lines has completed enrollment of more than 2,100 subjects- NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc.
View HTML
Toggle Summary Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
- Conference Call Scheduled for Thursday, November 2, 2017 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools